Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $38.57 Average PT from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $38.57.

A number of analysts have recently weighed in on the stock. Wedbush upped their target price on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. HC Wainwright restated a “buy” rating and issued a $46.00 price objective on shares of Zentalis Pharmaceuticals in a report on Wednesday, February 28th.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, CFO Melissa B. Epperly sold 2,573 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $11.44, for a total transaction of $29,435.12. Following the transaction, the chief financial officer now directly owns 451,449 shares of the company’s stock, valued at $5,164,576.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ZNTL. Eventide Asset Management LLC boosted its position in Zentalis Pharmaceuticals by 47.9% in the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock worth $175,134,000 after purchasing an additional 3,745,936 shares during the last quarter. Decheng Capital LLC purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth approximately $31,809,000. Vanguard Group Inc. boosted its holdings in shares of Zentalis Pharmaceuticals by 6.2% in the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock worth $105,047,000 after buying an additional 307,490 shares during the last quarter. Federated Hermes Inc. grew its position in Zentalis Pharmaceuticals by 10.9% during the fourth quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after buying an additional 212,872 shares during the period. Finally, Rafferty Asset Management LLC increased its holdings in Zentalis Pharmaceuticals by 79.4% during the fourth quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock valued at $5,456,000 after buying an additional 159,439 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $11.77 on Thursday. Zentalis Pharmaceuticals has a 1 year low of $9.56 and a 1 year high of $31.46. The firm has a 50-day moving average of $14.15 and a 200 day moving average of $13.93. The company has a market cap of $835.20 million, a P/E ratio of -2.59 and a beta of 1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.09. On average, equities research analysts expect that Zentalis Pharmaceuticals will post -3.72 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.